Table 1 Baseline characteristics in patients with a baseline imputed PaO2/FiO2 ≤ 200
Placebo (n = 131) | Auxora (n = 130) | Total (N = 261) | |
|---|---|---|---|
Male, n (%) | 92 (70.2%) | 84 (64.6%) | 176 (67.4%) |
Race | |||
White, n (%) | 98 (74.8%) | 85 (65.4%) | 183 (70.1%) |
Black, n (%) | 12 (9.2%) | 19 (14.6%) | 31 (11.9%) |
Asian | 5 (3.8%) | 9 (6.9%) | 14 (5.4%) |
Other/multiple* | 16 (12.2%) | 16 (12.3%) | 32 (12.3%) |
Hispanic, n (%) | 58 (44.3%) | 45 (34.6%) | 103 (39.5%) |
Mean age, years (SD) | 60.4 (12.3) | 59.4 (12.1) | 59.9 (12.2) |
65+ years of age, n (%) | 47 (35.9%) | 45 (34.6%) | 92 (35.2%) |
Mean BMI, kg/m2 (SD) | 32.0 (7.0) | 32.8 (8.8) | 32.4 (8.0) |
Mean time from symptom onset, days (SD) | 12.0 (5.9) | 12.2 (5.8) | 12.1 (5.8) |
Median time from hospitalization to randomization, days | 3.0 | 3.0 | 3.0 |
HFNC use, n (%) | 82 (62.6%) | 81 (62.3%) | 163 (62.5%) |
Mean baseline imputed PaO2/FiO2 value† (SD) | 105.1 (32.8) | 109.7 (36.8) | 107.4 (34.8) |
Baseline imputed PaO2/FiO2 ≤ 100, n (%) | 58 (44.3%) | 59 (45.4%) | 117 (44.8%) |
Baseline imputed PaO2/FiO2 101–200, n (%) | 73 (55.7%) | 71 (54.6%) | 144 (55.2%) |
Mean CRP, mg/L (SD) | 92.5 (67.6) | 93.1 (71.2) | 92.8 (69.2) |
Mean ferritin, ng/mL (SD) | 1050 (869) | 1027 (907) | 1039 (886) |
Hypertension, n (%) | 80 (61.1%) | 84 (64.6%) | 164 (62.8%) |
Diabetes, n (%) | 57 (43.5%) | 52 (40.0%) | 109 (41.8%) |
Hyperlipidemia, n (%) | 51 (38.9%) | 50 (38.5%) | 101 (38.7%) |
Former Smoker, n (%) | 34 (26.0%) | 39 (30.0%) | 73 (28.0%) |